InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
Globe Newswire•02/10/2026•07:30 ET
0
Key Highlights
- ➤InflaRx (IFRX) selected for Kidney Week 2026 late-breaking poster session
- ➤Izicopan poster presents pre-clinical kidney disease model data on October 22, 2026
- ➤Izicopan development planned for ANCA-associated vasculitis and additional renal indications
- ➤Izicopan achieved ≥90% blockade of C5a-induced neutrophil activation over 14-day dosing
- ➤Phase 2a data showed no reported safety signals of concern for izicopan
Jena, Germany, Oct. 02, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company has been selected for a late-breaking poster session at the American Society of Nephrology’s Kidney Week 2026, taking place in Denver, Colorado, USA, October 21 - 25.
Title: Izicopan, a Second-Generation Oral C5a Receptor 1 (C5aR1) Antagonist, Demonstrates Promising Therapeutic Potential in Kidney Disease Models.
Get started
Create a free account to read the full story.